Sharekhan

Senores Pharmaceuticals Ltd

Tue 5/05/2026,15:58:11 NSE: SENORES

₹ 882.05 -12.20 (-1.36%)
BUY NOW Buy Senores Pharmaceuticals Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Senores Pharmaceuticals Ltd

Tue 5/05/2026,16:1:0

Senores Pharmaceuticals Ltd

Tue 5/05/2026,15:58:11 | NSE : SENORES

₹ 882.05-12.20 (-1.36%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 891.10

Previous Close

₹ 894.25

Volume

176624

Mkt Cap ( Rs. Cr)

₹4062.16

High

₹ 903.85

Low

₹ 879.10

52 Week High

₹ 947.70

52 Week Low

₹ 475.00

Book Value Per Share

₹ 184.04

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Senores Pharmaceuticals Ltd

Your Vote -

Buy

80.00%

Hold

10.00%

Sell

10.00%

80.00%

10 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

882.05

200

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

200

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Senores Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Senores Pharma. - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    29 Apr 2026, 4:23PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td

  • Senores Pharma. - Disclosure under SEBI Takeover Regulations

    22 Apr 2026, 5:26PM Senores Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indi

  • Senores Pharma. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    7 Apr 2026, 5:20PM Senores Pharmaceuticals Limited has informed the Exchange about Submission of Reconciliation of Share Capital Audit Report for the quarter ended March

  • Senores Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    7 Apr 2026, 5:40PM As of March 2026, 45.82% is owned by Promoters and 54.18% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 39.54% and Fore

  • Senores Pharma. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    6 Apr 2026, 7:04PM Senores Pharmaceuticals Limited has informed the Exchange regarding Certificate pursuant to Regulation 74(5) of SEBI (DP)Regulations, 2018 for quarter

  • Senores Pharma. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    6 Apr 2026, 7:02PM Senores Pharmaceuticals Limited has informed the Exchange regarding Certificate pursuant to Regulation 74(5) of SEBI (DP)Regulations,2018 for quarter

  • Senores Pharma. - Press Release

    3 Apr 2026, 8:02PM Senores Pharmaceuticals Limited has informed the Exchange regarding media release

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    3 Apr 2026, 8:00PM Senores Pharmaceuticals Limited has informed the Exchange regarding Media Release

  • Senores Pharma. - General Updates

    3 Apr 2026, 7:42PM Senores Pharmaceuticals Limited has informed the Exchange regarding intimation under Regulation 30 of SEBI (LODR) Regulations, 2015

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Acquisition

    3 Apr 2026, 7:40PM Senores Pharmaceuticals Limited has informed the Exchange regarding intimation under Regulation 30 of SEBI (LODR) Regulations, 2015

  • Senores Pharma. - Allotment of Securities

    28 Mar 2026, 12:56PM Senores Pharmaceuticals Limited has informed the Exchange regarding allotment of 1170000 Convertible Equity Warrants

  • Senores Pharma. - Outcome of Board Meeting

    28 Mar 2026, 12:52PM Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on March 28, 2026.

  • Senores Pharma. - Trading Window

    27 Mar 2026, 12:02PM Senores Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regul

  • Senores Pharma. - Resignation

    17 Mar 2026, 4:40PM Senores Pharmaceuticals Limited has informed the Exchange regarding Resignation of Senior Management Personnel of the Company

  • Senores Pharma. - Appointment

    17 Mar 2026, 4:40PM Senores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Senior Management Personnel of the Company

  • Senores Pharma. - Intimation Regarding Changes In The Senior Management Personnel ('SMP') Of The Company

    17 Mar 2026, 4:44PM Senores Pharmaceuticals Limited has informed the Exchange regarding change in the senior management personnel (\SMP\) of the Company.

  • Senores Pharma. - Intimation Regarding Changes In The Senior Management Personnel ('SMP') Of The Company

    17 Mar 2026, 4:44PM Senores Pharmaceuticals Limited has informed the Exchange regarding change in the senior management personnel (\SMP\) of the Company.

  • Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    9 Mar 2026, 4:35PM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/Institutional Investor meet scheduled to be held on March 12, 2026.

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    9 Mar 2026, 4:33PM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/Institutional Investor meet scheduled to be held on March 12, 2026.

  • Senores Pharma. - Giving guarantees/indemnity/ becoming a surety for third party

    3 Mar 2026, 3:07PM Senores Pharmaceuticals Limited has informed the Exchange regarding issuance of Corporate Guarantee for the credit facilities availed by Senores Pharm

  • Senores Pharma. - Giving guarantees/indemnity/ becoming a surety for third party

    3 Mar 2026, 3:00PM Senores Pharmaceuticals Limited has informed the Exchange regarding issuance of Corporate Guarantee for the additional credit facilities availed by Ha

  • Senores Pharma. - Announcement Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Dis

    3 Mar 2026, 3:05PM Senores Pharmaceuticals Limited has informed the Exchange regarding issuance of Corporate Guarantee for the credit facilities availed by Senores Pharm

  • Senores Pharma. - Announcement Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Dis

    3 Mar 2026, 2:56PM Senores Pharmaceuticals Limited has informed the Exchange regarding issuance of Corporate Guarantee for the additional credit facilities availed by Ha

  • Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    2 Mar 2026, 3:26PM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/Institutional Investor meet scheduled to be held on March 09, 2026.

  • Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    2 Mar 2026, 3:21PM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/Institutional Investor meet scheduled to be held on March 06, 2026.

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    2 Mar 2026, 3:25PM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/Institutional Investor meet scheduled to be held on March 09, 2026.

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    2 Mar 2026, 3:18PM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/Institutional Investor meet scheduled to be held on March 06, 2026.

  • Senores Pharma. - General Updates

    13 Feb 2026, 5:55PM Senores Pharmaceuticals Limited has informed the Exchange regarding additional disclosures to the Notice of Extra-Ordinary General Meeting dated Janua

  • Senores Pharmaceuticals

    6 Apr 2026 , 11:07AM Senores Pharmaceuticals : The company has announced the formation of a strategic joint venture in the United States through its wholly owned subsidiary, marking a significant expansion into the federal government procurement market. This partnership strategically positions Senores to facilitate supply of its pharmaceutical product portfolio to multiple U.S. government sectors including federal government contracts, veterans affairs supply agreements, military supply contracts, and long-term national contracts. The joint venture framework provides the company with specialized credentials necessary to participate in the high-entry-barrier U.S. government procurement market, specifically targeting federal and defense needs.

  • Senores Pharmaceuticals Ltd

    12 Dec 2025 , 10:37AM Senores pharma: launches Deferiprone Tablets USP (500mg & 1000mg) in the U.S., bioequivalent to Ferriprox. Dr. Reddy’s Laboratories Inc. to market the product in the U.S. - Deferiprone Tablets had ~$70M in U.S. sales for the 12 months ending October 2025. Positive

  • Senores Pharmaceuticals

    6 Nov 2025 , 1:19PM Senores Pharmaceuticals : The company reported two major developments – Its wholly owned subsidiary, Senores Pharmaceuticals Inc. (SPI) acquired 51% stake in Zoraya Pharmaceuticals LLC, Delaware, USA through subscription of membership interest.With this move, Zoraya has become a step-down subsidiary of the Company and bolsters its operations as well as product development strengths in the US. Secondly, its material subsidiary, Havix Group Inc. D/B/A Aavis Pharmaceuticals, based in Georgia, USA, has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration after a successful inspection in July 2025. The inspection concluded with three minor observations, all of which have been resolved to the satisfaction of the USFDA, marking the closure of the inspection.

  • Senores Pharmaceuticals Ltd

    13 Aug 2025 , 8:59AM Senores Pharmaceuticals, through its US subsidiary, has signed an agreement to acquire two USFDA-approved ANDAs from Teva Pharmaceuticals USA. The US market opportunity is estimated at ~USD 38 mn (IQVIA, Dec 2024) and ~USD 120 mn (Symphony, Jun 2025). The acquisition will be funded from IPO proceeds, in line with the stated IPO objectives.

  • Senores Pharmaceuticals acquires ANDA for Roflumilast

    21 Feb 2025 , 12:36PM Senores Pharmaceuticals acquires ANDA for Roflumilast 250 mcg and 500 mcg tablets
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Senores Pharmaceuticals Ltd stock 

Name March-25 March-24 March-23 March-22
Assets 801.93 260.871 99.332 48.2313
Liabilities 801.93 260.871 99.332 48.2313
Equity 46.05 30.505 9.818 8.7422
Gross Profit -7.28 -0.062 -1.78 0.9342
Net Profit 3.69 0.814 1.199 0.293
Cash From Operating Activities -20.4 -62.818 -43.414 -12.1977
NPM(%) 9.57 2.39 9.68 1.84
Revenue 38.54 34.006 12.382 15.8508
Expenses 45.82 34.068 14.162 14.9166
ROE(%) 0.43 0.09 0.14 0.03

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Senores Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 758.60 3.68 45.05 509.45 301.39 0.66
Lotus Eye Hospital and Institute Ltd 116.39 -0.03 375.45 1856.38 3.55 0.00
Vaishali Pharma Ltd 7.73 4.04 0.00 11645.70 3.13 0.00
Astec Lifesciences Ltd 673.75 -5.45 0.00 1750.61 -363.15 0.00

Company Info

Our Company was originally incorporated as "Senores Pharmaceuticals Private Limited" a private limited company under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.The name of the Company was thereafter changed to "Senores Pharmaceuticals Limited" upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited 2022 - Started the domestic business with a launch of the critical care injectables 2024 - Launched first CMO product in the US with Jubilant Cadista. 2025-Senores Pharmaceuticals receives Philippine FDA approval for 10 products.-The Company Acquired of 6730 equity shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals.

Our Company was originally incorporated as "Senores Pharmaceuticals Private Limited" a private limited company under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.The name of the Company was thereafter changed to "Senores Pharmaceuticals Limited" upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited 2022 - Started the domestic business with a launch of the critical care injectables 2024 - Launched first CMO product in the US with Jubilant Cadista. 2025-Senores Pharmaceuticals receives Philippine FDA approval for 10 products.-The Company Acquired of 6730 equity shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals.

Read More

Parent Organisation

Senores Pharmaceuticals Ltd.

Founded

26/12/2017

Managing Director

Mr.Swapnil Jatinbhai Shah

NSE Symbol

SENORESEQ

FAQ

The current price of Senores Pharmaceuticals Ltd is ₹ 882.05.

The 52-week high for Senores Pharmaceuticals Ltd is ₹ 903.85 and the 52-week low is ₹ 879.10.

The market capitalization of Senores Pharmaceuticals Ltd is currently ₹ 4062.16. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Senores Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Senores Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Senores Pharmaceuticals Ltd shares.

The CEO of Senores Pharmaceuticals Ltd is Mr.Swapnil Jatinbhai Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT